(Total Views: 324)
Posted On: 01/06/2020 12:23:54 PM
Post# of 1418
Form 6-K
Todos Medical Ltd.Report
January 5, 2020
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Appointment of New Directors and Officers
On January 5, 2020, Todos Medical Ltd. (the “Company”) appointed Mr. Gerald Commissiong as Chief Executive Officer (CEO) and Director of the Company. In addition, Mr. Daniel Hirsch was promoted to Chief Financial Officer and appointed a Director of the Company on January 5, 2020. Mr. Hirsch previously served as the Company’s Director of Investor Relations. Mr. Commissiong and Mr. Hirsch were appointed primarily to transition the Company’s headquarters from Israel to the United States.
Dr. Herman Weiss, an existing director of the Company, was appointed Chairman of the Board.
Mr. Commissiong is currently a director and President & CEO of Amarantus Bioscience Holdings, Inc. and is interim-CEO of Breakthrough Diagnostics, Inc., Todos’ joint venture with Amarantus. Mr. Commissiong has been responsible for Amarantus’ strategic transactions, licensing, research collaborations, mergers & acquisitions in therapeutics and diagnostics, as well as fund raising, having raised over of $50 million since inception. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University.
Resignation of Officer
Concurrent with Gerald Commissiong’s appointment as CEO, Dr. Herman Weiss resigned as CEO of the Company and will focus solely on his new role as Chairman of the Board of Directors.
https://sec.report/Document/0001213900-20-000231/
Todos Medical Ltd.Report
January 5, 2020
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Appointment of New Directors and Officers
On January 5, 2020, Todos Medical Ltd. (the “Company”) appointed Mr. Gerald Commissiong as Chief Executive Officer (CEO) and Director of the Company. In addition, Mr. Daniel Hirsch was promoted to Chief Financial Officer and appointed a Director of the Company on January 5, 2020. Mr. Hirsch previously served as the Company’s Director of Investor Relations. Mr. Commissiong and Mr. Hirsch were appointed primarily to transition the Company’s headquarters from Israel to the United States.
Dr. Herman Weiss, an existing director of the Company, was appointed Chairman of the Board.
Mr. Commissiong is currently a director and President & CEO of Amarantus Bioscience Holdings, Inc. and is interim-CEO of Breakthrough Diagnostics, Inc., Todos’ joint venture with Amarantus. Mr. Commissiong has been responsible for Amarantus’ strategic transactions, licensing, research collaborations, mergers & acquisitions in therapeutics and diagnostics, as well as fund raising, having raised over of $50 million since inception. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University.
Resignation of Officer
Concurrent with Gerald Commissiong’s appointment as CEO, Dr. Herman Weiss resigned as CEO of the Company and will focus solely on his new role as Chairman of the Board of Directors.
https://sec.report/Document/0001213900-20-000231/
(1)
(0)
